HPP737

HPP737 is a novel, potent, orally administered small molecule that acts as a selective phosphodiesterase type 4 (PDE4) inhibitor. It was discovered by vTv Therapeutics and is being developed for the treatment of inflammatory diseases such as psoriasis, atopic dermatitis, and chronic obstructive pulmonary disease (COPD). HPP737 demonstrates increased selectivity for the PDE4B2 isoform over PDE4D, with limited central nervous system penetration and higher potency compared to currently approved PDE4 inhibitors. The drug has shown robust inhibition of pro-inflammatory cytokines including IL23 and TNF-alpha in preclinical models. Clinical studies indicate that HPP737 is well tolerated with minimal gastrointestinal side effects—a common limitation of other oral PDE4 inhibitors—supporting its potential as an improved therapy for moderate-to-severe psoriasis and other inflammatory conditions[1][2][6][7].